The nice
people at Transfusion News sent their update today. D-genotyping, more about
the use of convalescent plasma (there’s a lot of contradictory stuff being
said about this)… all good stuff.
RHD Genotyping in Transfusion Practice Could Identify Novel RHD Alleles and Conserve D-negative Blood |
 January 20, 2021
Partial
D phenotypes (with altered D epitopes) and weak D phenotypes (with a
reduced number of D antigens present on RBCs) are difficult to
distinguish based on serology alone. Thus, genotyping the RHD locus is
recommended to limit the risk of alloimmunization and to avoid
unnecessary use of RhIG and D- blood. [Read More]
|
|
|
Early Convalescent Plasma Therapy Helps Prevent Severe COVID-19 |
 January 12, 2021
COVID-19
convalescent plasma administered late in the course of disease has not
shown clear benefits, but some studies suggest that early transfusion
may be efficacious. In order to determine if convalescent plasma
administered soon after infection may help to prevent severe disease in
older patients, researchers in Argentina randomized 160 patients aged 65
or older to receive either convalescent plasma (N=80) or placebo (N=80)
within 72 hours of symptom onset. [Read More]
|
No comments:
Post a Comment